This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Vaughn, D. J. Articles by Markowitz, A. B. Search for Related Content PubMed PubMed Citation Articles by Vaughn, D. J. Articles by Markowitz, A. B. Social Bookmarking                            What's this?

Phase II Trial of Weekly Paclitaxel in Patients With Previously Treated Advanced Urothelial Cancer

From the University of Pennsylvania Cancer Center, Philadelphia, PA; Northern Virginia Oncology Group, Fairfax, VA; Barbara Ann Karmanos Cancer Institute, Detroit, MI; Sidney Kimmel Cancer Center, San Diego, CA; and St Joseph Regional Cancer Center, Bryan, TX.

Address reprint requests to David J. Vaughn, MD, University of Pennsylvania Cancer Center, 3400 Spruce St, 16 Penn Tower, Philadelphia, PA 19104; email: djv{at}mail.med.upenn.edu

PURPOSE: We evaluated the efficacy and toxicity of weekly paclitaxel in patients with previously treated advanced urothelial cancer.

PATIENTS AND METHODS: Patients with urothelial cancer who had received one prior systemic chemotherapy regimen for advanced disease and had evidence of disease progression were eligible for enrollment. Patients received paclitaxel 80 mg/m² by 1-hour intravenous infusion weekly. A cycle of therapy consisted of four weekly treatments.

RESULTS: The study enrolled 31 patients. Mean age was 66 years, and 45% of patients had three or more involved metastatic sites. Only 26% of patients had responded to prior chemotherapy. The median number of cycles delivered was three (range, one to eight) at a mean weekly paclitaxel dose of 79 mg/m². Three patients achieved a partial response (10%; 95% confidence interval, 0% to 20%). Median time to progression was 2.2 months, and median overall survival time was 7.2 months. Therapy was well tolerated with minimal hematologic toxicity. Grade 3 nonhematologic toxicities were also uncommon.

CONCLUSION: Although the overall response rate to weekly paclitaxel in patients with previously treated advanced urothelial cancer was modest, the chemotherapy-refractory nature of the study population should be considered.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				G. Sonpavde, A. A. Elfiky, and J. E. Rosenberg Review: Novel agents for advanced bladder cancer Therapeutic Advances in Medical Oncology, July 1, 2009; 1(1): 37 - 50. [Abstract] [PDF]

				T. Suyama, T. Ueda, S. Fukasawa, Y. Imamura, K. Nakamura, K. Miyasaka, T. Sazuka, K.-i. Egoshi, N. Nihei, M. Hamano, et al. Combination of Gemcitabine and Paclitaxel as Second-line Chemotherapy for Advanced Urothelial Carcinoma Jpn. J. Clin. Oncol., April 1, 2009; 39(4): 244 - 250. [Abstract] [Full Text] [PDF]

				H. Akaza, S. Naito, M. Usami, T. Miki, N. Miyanaga, H. Taniai, and and the Japanese Gemcitabine Study Group Efficacy and Safety of Gemcitabine Monotherapy in Patients with Transitional Cell Carcinoma after Cisplatin-Containing Therapy: A Japanese Experience Jpn. J. Clin. Oncol., April 23, 2007; (2007) hym011v1. [Abstract] [Full Text] [PDF]

				J. A. Garcia and R. Dreicer Systemic Chemotherapy for Advanced Bladder Cancer: Update and Controversies J. Clin. Oncol., December 10, 2006; 24(35): 5545 - 5551. [Abstract] [Full Text] [PDF]

				C. J. Sweeney, B. J. Roth, F. F. Kabbinavar, D. J. Vaughn, M. Arning, R. E. Curiel, C. K. Obasaju, Y. Wang, S. J. Nicol, and D. S. Kaufman Phase II Study of Pemetrexed for Second-Line Treatment of Transitional Cell Cancer of the Urothelium J. Clin. Oncol., July 20, 2006; 24(21): 3451 - 3457. [Abstract] [Full Text] [PDF]

				M. D. Galsky The Role of Taxanes in the Management of Bladder Cancer Oncologist, November 1, 2005; 10(10): 792 - 798. [Abstract] [Full Text] [PDF]